Eyenovia (NASDAQ:EYEN) Earns Hold Rating from Brookline Capital Management

Brookline Capital Management restated their hold rating on shares of Eyenovia (NASDAQ:EYEN) in a research report sent to investors on Friday,Benzinga reports.

EYEN has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Wednesday, November 13th. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research report on Friday.

Eyenovia Stock Performance

Eyenovia stock opened at $0.11 on Friday. Eyenovia has a 1-year low of $0.09 and a 1-year high of $2.57. The firm has a market cap of $7.11 million, a P/E ratio of -0.15 and a beta of 1.75. The firm has a 50-day moving average of $0.48 and a 200-day moving average of $0.70. The company has a current ratio of 0.74, a quick ratio of 0.27 and a debt-to-equity ratio of 0.58.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the previous year, the business posted ($0.18) EPS. Sell-side analysts expect that Eyenovia will post -0.5 EPS for the current year.

Insider Activity

In other Eyenovia news, CEO Michael M. Rowe bought 50,000 shares of the stock in a transaction dated Monday, August 26th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the completion of the acquisition, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This trade represents a 151.85 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 7.10% of the company’s stock.

Hedge Funds Weigh In On Eyenovia

A number of hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in Eyenovia in the 2nd quarter worth approximately $3,601,000. Vanguard Group Inc. raised its stake in Eyenovia by 25.2% during the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after buying an additional 360,924 shares during the last quarter. Geode Capital Management LLC raised its stake in Eyenovia by 36.6% during the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after buying an additional 149,471 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Eyenovia by 1,444.4% during the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares during the last quarter. Finally, SkyView Investment Advisors LLC purchased a new stake in Eyenovia during the 2nd quarter valued at $87,000. 25.84% of the stock is currently owned by hedge funds and other institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.